EDEstefania Diaz-Mesa

Estefania Diaz-Mesa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Estefania Diaz-Mesa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum Melatonin at Admission and Discharge in Schizophrenia: A Prospective Longitudinal Controlled Study

    by Armando Luis Morera-Fumero, Estefanía Diaz-Mesa, Silvia Yelmo-Cruz, Pedro Abreu-González, María Lourdes Fernández-López

    Schizophrenia is associated with circadian and neuroendocrine disturbances, but whether circulating melatonin changes with acute clinical state remains uncertain. This prospective longitudinal controlled study measured serum melatonin at 12:00 and 00:00 in 43 hospitalized patients after admission and before discharge, and during one session in 42 healthy controls. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Nonparametric comparisons used family-specific Holm adjustment; exploratory correlations used false-discovery-rate control. In comparisons without covariate adjustment, midday concentrations were higher in patients at admission and discharge (Holm p = 0.013 and 0.007), but the differences did not remain significant after Holm correction in exploratory models adjusted for BMI, age, and sex (29 patients and 40 controls). Median within-patient changes were −0.14 pg/mL at 12:00 (95% CI −0.27 to 0.74) and 0.00 pg./mL at 00:00 (95% CI −2.00 to 6.35); both Holm p = 1.000. Total PANSS decreased by a median of 14 points among 24 complete pairs. No change-PANSS correlation survived multiplicity correction. Two daily samples demonstrate a midday–midnight concentration difference but cannot characterize circadian phase, amplitude, or total secretion. No short-term melatonin change was detected during hospitalization; this does not establish equivalence or confirm or exclude trait-biomarker status. State-marker utility remains uncertain, and patient–control differences may reflect medication, smoking, or confounding by assay plate.

  • Open Access

    Longitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Clinical Improvement in Schizophrenia: An Admission-Discharge Study

    by Armando L. Morera-Fumero, José J. Tascón-Cervera, Estefania Diaz-Mesa, Silvia Yelmo-Cruz, Pedro Abreu-González, María Lourdes Fernandez-Lopez

    Background/Objectives: Schizophrenia pathophysiology has been linked to immune dysregulation, but the role of interleukin-33 (IL-33) during acute psychotic relapse remains insufficiently investigated. This exploratory admission–discharge study aimed to evaluate serum IL-33 levels in inpatients with paranoid schizophrenia and in healthy controls. Methods: Serum IL-33 was measured at midday (12:00 h) and midnight (24:00 h) in 21 inpatients with paranoid schizophrenia and 21 age- and sex-matched healthy controls (HC). Patients were sampled at admission and discharge. HC underwent one sampling day, with blood collected at both 12:00 h and 24:00 h, during the interval between the patients’ admission and discharge assessments. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: PANSS positive and general psychopathology scores decreased from admission to discharge (p < 0.001 and p = 0.008, respectively). Serum IL-33 concentrations were descriptively higher in patients than in HC, but between-group differences were not statistically significant. Midnight serum IL-33 increased from admission to discharge (214.9 ± 358.0 vs. 241.2 ± 379.4 pg/mL; p = 0.028), whereas the midday change was nonsignificant. Age was inversely correlated with IL-33 in patients; associations with antipsychotic dosage and sex were not statistically significant. Conclusions: The midnight increase in IL-33 accompanied clinical improvement, but medication, hospitalization, age, and smoking remain potential confounders. These exploratory findings warrant replication and do not establish IL-33 as a diagnostic or state biomarker.

  • Open Access

    Longitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Recovery in Schizophrenia: An Admission-Discharge Study

    by Armando L. Morera-Fumero, José J. Tascón-Cervera, Estefania Diaz-Mesa, Silvia Yelmo-Cruz, Pedro Abreu-González, María Lourdes Fernandez-Lopez

    Immune-inflammatory dysregulation plays a central role in the pathophysiology of schizophrenia (SCZ). Interleukin-33 (IL-33), a pleiotropic alarmin cytokine of the IL-1 family, modulates neuroimmune communication, glial activation, and tissue repair, yet its involvement in psychotic disorders remains poorly characterized. This study examined serum IL-33 concentrations in 21 patients experiencing an acute psychotic relapse and 21 age- and sex-matched healthy controls (HC). Using a longitudinal design, we measured serum IL-33 by ELISA at 12:00 h and 24:00 h on the day after admission and the day before discharge in patients, alongside comprehensive clinical assessment with the Positive and Negative Syndrome Scale (PANSS). Patients with SCZ exhibited significantly lower IL-33 levels than HC at all time points (p < 0.05). Notably, IL-33 concentrations increased significantly at midnight from admission to discharge (p = 0.028), paralleling clinical improvement in PANSS positive and general psychopathology scores. A robust inverse correlation between age and IL-33 levels was observed in both patients and controls (p < 0.05), independent of sex, smoking status, sampling time, and antipsychotic dosage. These findings provide the first longitudinal evidence that IL-33 is reduced during acute psychotic episodes and rises in association with clinical recovery, supporting its role as a state-dependent biomarker. Our results highlight the involvement of alarmin signalling in the neuroimmune dysregulation underlying psychotic relapse and underscore the importance of age as a critical covariate in immunopsychiatric research.